NCT00086892已完成2 期
A Phase II Evaluation of Cetuximab (C225, NSC #714692) in Combination With Carboplatin (NSC #241240) in the Treatment of Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 76
研究概览
简要总结
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy such as carboplatin work in different ways to stop tumor cells from dividing so they stop growing or die. Combining cetuximab with carboplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cetuximab together with carboplatin works in treating patients with recurrent ovarian epithelial cancer or primary peritoneal cancer.
详细描述
OBJECTIVES:
- Determine the antitumor activity of cetuximab and carboplatin in patients with recurrent platinum-sensitive ovarian epithelial or primary peritoneal cancer.
- Determine the nature and degree of toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1, 8 , and 15. Patients also receive carboplatin IV after cetuximab administration on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed ovarian epithelial or primary peritoneal cancer
- •Recurrent disease
- •Measurable disease
- •At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques, including palpation, plain x-ray, CT scan, or MRI OR ≥ 10 mm by spiral CT scan
- •Target lesion not within previously irradiated field
- •Received 1 prior platinum-based chemotherapy regimen for primary disease containing carboplatin, cisplatin, or other organoplatinum compound
- •Initial treatment may have included high-dose, consolidation, or extended therapy administered after surgical or non-surgical assessment
- •Patients who had not received prior paclitaxel therapy may have received a second regimen that included paclitaxel
- •Platinum-sensitive disease
- •Treatment-free interval without clinical evidence of progressive disease for more than 6 months after response to a prior platinum-based regimen
- •If there is another concurrently active GOG-0146 series protocol (non-platinum-based therapy), must have had a treatment-free interval of more than 12 months unless ineligible for the other protocol* NOTE: *Applies whether or not both protocols are available at the same participating center
- •Must have available tissue block or unstained sections from primary tumor, interval debulking, or secondary debulking
- •Not eligible for a higher priority GOG protocol (i.e., any active phase III GOG protocol for the same patient population)
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Life expectancy
- •Not specified
- •Hematopoietic
- •Absolute neutrophil count ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- •SGOT ≤ 2.5 times ULN
- •Alkaline phosphatase ≤ 2.5 times ULN
- •Creatinine ≤ 1.5 times ULN
- •Cardiovascular
- •No uncontrolled hypertension
- •No unstable angina
- •No congestive heart failure
- •No uncontrolled arrhythmias within the past 6 months
- •No other significant cardiac disease
- •No uncontrolled seizure disorder
- •No active neurological disease
- •No neuropathy > grade 1
- •No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
- •No active infection requiring antibiotics
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •No prior anti-epidermal growth factor receptor (EGFR) antibody therapy
- •No prior chimerized or murine monoclonal antibody therapy
- •At least 3 weeks since prior biologic or immunologic therapy for the malignancy
- •Chemotherapy
- •See Disease Characteristics
- •Recovered from prior chemotherapy
- •No prior cytotoxic chemotherapy for recurrent disease, including retreatment with initial chemotherapy regimens
- •Endocrine therapy
- 另有 12 项未显示
排除标准
- 未提供
研究者
研究点 (76)
Loading locations...
相似试验
已完成
2 期
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung CancerLung CancerNCT00081302Radiation Therapy Oncology Group
已完成
2 期
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin ChemotherapyHead and Neck CancerNCT00004865Jonsson Comprehensive Cancer Center
撤回
2 期
Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal CarcinomaColorectal CarcinomaNCT00725400American Scitech International450
已完成
2 期
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and NeckHead and Neck CancerNCT00096174Eastern Cooperative Oncology Group69
已完成
2 期
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck CancerHead and Neck CancerNCT00005814Memorial Sloan Kettering Cancer Center